mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy.
Lisa Maria RiedmayrKlara Sonnie HinrichsmeyerStefan Bernhard ThalhammerDavid Manuel MittasNina KarguthDina Yehia OtifySybille BöhmValentin Johannes WeberMichael David BartoschekVictoria SplithManuela BrümmerRaphael FerreiraNanda BoonGabriele Maria WögensteinChristian GrimmJan WijnholdsVerena MehlfeldStylianos MichalakisStefanie FenskeMartin BielElvir BecirovicPublished in: Nature communications (2023)
Large genes including several CRISPR-Cas modules like gene activators (CRISPRa) require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, REVeRT enabled the reconstitution of full-length ABCA4 after intravitreal injection in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications.
Keyphrases
- gene therapy
- crispr cas
- genome editing
- genome wide
- genome wide identification
- mouse model
- endothelial cells
- poor prognosis
- sars cov
- gene expression
- dna methylation
- copy number
- transcription factor
- induced pluripotent stem cells
- vascular endothelial growth factor
- single cell
- drug delivery
- cancer therapy
- diabetic retinopathy
- risk assessment
- ultrasound guided
- optical coherence tomography